Romiplostim plus steroids vs steroids alone for newly diagnosed ITP
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests if adding romiplostim (a drug that helps make platelets) to standard steroid treatment works better than steroids alone for adults who have not been treated for ITP before. It is for people with low platelet counts and may help reduce bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with primary immune thrombocytopenia (ITP; a condition where your immune system destroys platelets) and have not received any prior ITP treatment
- Your platelet count is very low: less than 30 billion per liter, or less than 50 billion per liter with significant bleeding
- You do not have a history of having your spleen removed
- You are not currently taking blood thinners (anticoagulants) or antiplatelet medicines like aspirin or clopidogrel
- You have no major liver or kidney problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if eltrombopag, a medication that helps the body make more platelets, works as the first treatment for people newly diagnosed with immune thrombocytopenia (ITP, a condition where the immune system destroys platelets, causing bleeding problems). It may help raise your platelet count and reduce bleeding risk.
This trial tests a combination of romiplostim (a platelet-boosting drug) and steroids as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). It aims to see if this approach can safely and effectively raise platelet counts.
This trial tests a new combination of two medicines—romiplostim N01 (a shot to raise platelets) and rituximab (an infusion that calms the immune system)—for people with primary immune thrombocytopenia (ITP) who have not had enough improvement from oral TPO-RA pills like hetrombopag or eltrombopag. It aims to see if this combination works better and is safe.
This trial tests romiplostim, a weekly injection, for patients with ITP (a blood disorder where the body destroys its own platelets) who did not respond to or could not tolerate oral medications. It aims to help raise platelet counts and reduce bleeding risk.
This trial tests whether a weekly injection of romiplostim can safely raise platelet counts in children with chronic immune thrombocytopenia (ITP) that has not improved with standard treatments. If effective, it may reduce bleeding risk and help children avoid more severe complications.
This study tests a combination of multiple drugs given in sequence to adults with newly diagnosed immune thrombocytopenia (ITP), a condition of low platelets. The goal is to see if this approach improves platelet counts and is safe.
Hear when a new Primary Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.